The pharmaceutical company Roche has announced possible stock issues concerning the medicine RoActemra (IV and SC) because of the off-label use for covid-19 patients.
KBVR-SRBR has prepared a document stating our position towards this problem.
With this document we want to make clear that KBVR-SRBR regrets this stock issue and we ask RIZIV/INAMI for a straight forward solution in the reimbursement process. However, we require that the available stock will be used first for patients with RA who are already being treated with RoActemra
This document will be spread among all rheumatologists, patients, RIZIV/INAMI, Pharma.be and Roche.
Roche has promised to keep us informed about the situation.